Jardiance Cannabis Interaction Profile

How Empagliflozin Works and Why Co-exposures Matter

Empagliflozin blocks the SGLT2 transporter in the proximal renal tubule, causing urinary glucose excretion of roughly 70 grams per day in patients with type 2 diabetes at the 10 mg dose [1]. That glucosuria lowers plasma glucose independent of insulin and creates an osmotic diuresis that reduces plasma volume by an estimated 200 to 400 mL within the first weeks of therapy [2].

The EMPA-REG OUTCOME Foundation

The cardiovascular benefits of empagliflozin were confirmed in EMPA-REG OUTCOME (N=7,020), where the 10 mg and 25 mg doses together reduced the three-point MACE composite by 14% versus placebo (hazard ratio 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority and P=0.04 for superiority) [3]. That trial excluded patients with significant comorbidities including heavy substance use, so the safety data do not extend directly to cannabis consumers.

Volume Depletion as the Interaction Fulcrum

Because SGLT2 inhibition produces ongoing fluid losses, any co-exposure that adds vasodilation or suppresses compensatory autonomic responses amplifies hypotension risk. The FDA-approved prescribing information for empagliflozin explicitly lists "concomitant use of diuretics, ACE inhibitors, angiotensin receptor blockers, or NSAIDs" and "impaired renal function" as factors that heighten volume-depletion risk [4]. Cannabis acts on cannabinoid receptor type 1 (CB1) in vascular smooth muscle, producing systemic vasodilation and a transient drop in blood pressure that may last 30 to 60 minutes after inhalation [5].

The Pharmacodynamic Overlap Between Cannabis and Jardiance

Blood Pressure Effects

Delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, causes an initial tachycardia followed by dose-dependent hypotension. A 2019 systematic review in the European Journal of Preventive Cardiology (pooled N=1,843 across 24 studies) found that acute cannabis use raised heart rate by a mean of 7.9 beats per minute and transiently lowered diastolic blood pressure [5]. Empagliflozin reduces systolic blood pressure by approximately 3 to 5 mmHg through its diuretic mechanism [2]. The combination may produce orthostatic hypotension, particularly in older adults, those on antihypertensive agents, or those who are already volume-depleted.

Patients on Jardiance should sit or lie down after cannabis use if they feel lightheaded. Stand slowly. That simple precaution reduces fall risk substantially.

Glucose Sensing and Symptom Masking

Cannabis impairs the hypothalamic glucose-sensing pathways that generate hunger and early hypoglycemia warning signals [6]. Empagliflozin itself causes little to no hypoglycemia as monotherapy because it does not stimulate insulin secretion [1]. However, many patients with type 2 diabetes use empagliflozin alongside sulfonylureas or insulin. In that context, cannabis-induced blunting of counter-regulatory awareness could cause patients to miss early hypoglycemic symptoms, especially at plasma glucose concentrations below 70 mg/dL.

Appetite, Caloric Intake, and Glycemic Variability

THC stimulates appetite via CB1 receptors in the hypothalamus, and a single cannabis session may increase caloric intake by 30 to 40% in controlled studies [6]. Because empagliflozin relies partly on caloric restriction and carbohydrate reduction to maintain glycemic control, binge eating after cannabis use could blunt the drug's glucose-lowering effect transiently. Continuous glucose monitor (CGM) data from observational reports suggest that post-cannabis glucose excursions can reach 180 to 220 mg/dL within 90 minutes of a high-carbohydrate meal in patients on SGLT2 inhibitors, though this has not been studied in a controlled trial.

Euglycemic DKA: The Most Serious Interaction Risk

What Euglycemic DKA Is

SGLT2 inhibitors shift metabolism toward fatty acid oxidation and ketogenesis, even when blood glucose is near-normal. The FDA issued a Drug Safety Communication in 2015 warning about this risk across the entire SGLT2 inhibitor class, including empagliflozin [7]. Euglycemic DKA (blood glucose often <250 mg/dL with pH <7.3 and elevated ketones) has been reported in patients who were fasting, ill, or had reduced carbohydrate intake.

How Cannabis Raises the DKA Risk Signal

Cannabinoid hyperemesis syndrome (CHS) is a well-documented condition in heavy, long-term cannabis users. It produces cyclical vomiting, dehydration, and the inability to tolerate oral intake [8]. A 2018 case series in the Annals of Emergency Medicine described patients presenting with CHS who had simultaneous metabolic acidosis. Vomiting and reduced oral carbohydrate intake are precisely the physiological conditions that trigger SGLT2-inhibitor-associated euglycemic DKA. The combination of CHS-induced vomiting and ongoing glucosuria from empagliflozin creates a scenario where ketone production can outpace clearance even with relatively preserved glucose levels.

Prescribers should instruct any patient on Jardiance who develops persistent vomiting to hold the dose and check urine ketones. This guidance applies whether the vomiting stems from cannabis, illness, or another cause [4].

Reported Cases and FDA Adverse Event Data

As of the 2020 updated FDA safety communication on SGLT2 inhibitors and DKA, the agency had received several hundred spontaneous reports of DKA across the drug class [7]. The FDA's MedWatch database does not routinely code concurrent cannabis use, so the true overlap is unknown. However, the mechanistic plausibility is strong enough that multiple endocrinology professional societies, including the American Association of Clinical Endocrinology (AACE), advise holding SGLT2 inhibitors during any prolonged illness or fasting state [9].

The AACE 2023 Diabetes Management Algorithm states: "SGLT2 inhibitors should be withheld during acute illness, surgery, or prolonged fasting due to risk of ketoacidosis" [9]. That recommendation covers the clinical scenario created by cannabinoid hyperemesis syndrome.

Can You Drink Alcohol on Jardiance?

The alcohol question mirrors the cannabis question in several ways.

Shared Mechanisms with Cannabis Risk

Alcohol causes vasodilation, diuresis, and impairs counter-regulatory hormonal responses to hypoglycemia. Empagliflozin already promotes osmotic diuresis. Together, alcohol and empagliflozin can produce additive volume depletion, worsening orthostatic hypotension. A 2017 review in Diabetes Care noted that alcohol consumption at more than two standard drinks per day was associated with increased DKA risk in patients on SGLT2 inhibitors, based on mechanistic data and case reports [10].

Practical Guidance for Alcohol Use

Moderate alcohol consumption (one standard drink per day for women, two for men, per CDC definitions) is unlikely to cause acute harm in most patients on empagliflozin who are otherwise stable [11]. Binge drinking is a different matter entirely. Vomiting from alcohol intoxication triggers the same euglycemic DKA pathway as CHS. Patients should hydrate aggressively, avoid skipping meals, and hold empagliflozin the morning after heavy alcohol use if they feel unwell.

Pharmacokinetic Considerations: Does Cannabis Change Empagliflozin Blood Levels?

CYP450 and UGT Enzyme Pathways

Empagliflozin is metabolized primarily by uridine diphosphate glucuronosyltransferase (UGT) enzymes, specifically UGT1A3, UGT1A8, UGT1A9, and UGT2B7 [4]. THC is metabolized by CYP2C9 and CYP3A4. Cannabidiol (CBD) is a moderate inhibitor of CYP2C9, CYP3A4, and UGT1A9 [12].

That UGT1A9 overlap is worth noting. CBD inhibits UGT1A9 in vitro, and UGT1A9 is a primary glucuronidation pathway for empagliflozin. If CBD reduces UGT1A9 activity in vivo to a clinically meaningful degree, empagliflozin plasma levels could rise, potentially increasing both efficacy and adverse effects.

What the Evidence Actually Shows

No published human pharmacokinetic study has measured empagliflozin blood levels in the presence of CBD or THC. The in vitro inhibition data for CBD on UGT1A9 come from liver microsome experiments, and translation to in vivo clinical effect is uncertain [12]. The FDA's guidance on drug interaction studies acknowledges that UGT inhibition in vitro does not reliably predict in vivo outcomes without clinical data [13].

The most accurate statement: a pharmacokinetic interaction between CBD and empagliflozin is biologically plausible but unconfirmed in humans.

A Clinical Decision Framework for Empagliflozin Patients Who Use Cannabis

Patients using Jardiance who also use cannabis can be stratified by risk level using the following approach:

Low-risk profile. Occasional cannabis use (fewer than once per week), inhalation or oral route, no concurrent sulfonylurea or insulin, normal renal function (eGFR above 60 mL/min/1.73m2), no history of DKA, and no orthostatic symptoms at baseline.

Moderate-risk profile. Regular cannabis use (weekly or more), concurrent antihypertensives, eGFR between 30 and 60, or occasional prior orthostatic symptoms. These patients need blood pressure monitoring at home and a clear sick-day action plan.

High-risk profile. Daily heavy cannabis use, history of CHS, concurrent insulin or sulfonylurea, eGFR below 30, or prior episode of euglycemic DKA. These patients should discuss with their prescriber whether empagliflozin is appropriate given their pattern of cannabis use, or whether they should hold empagliflozin on days of heavy use.

The sick-day rule for all risk levels: stop Jardiance, check urine ketones, hydrate aggressively, and call a provider if ketones are moderate or large, or if vomiting prevents oral intake for more than four hours [4].

What to Tell Your Prescriber

Disclosure matters. A 2021 survey published in JAMA Internal Medicine found that 70% of medical cannabis users did not disclose use to their primary care provider, often citing fear of judgment [14]. That undisclosure prevents prescribers from adjusting sick-day protocols or monitoring plans.

Patients should tell their Jardiance prescriber: how often they use cannabis, which route (inhaled, edible, oil), whether they use primarily THC or CBD products, and whether they have ever experienced prolonged nausea or vomiting from cannabis.

Prescribers can respond by providing a written sick-day card specifying when to hold Jardiance (any vomiting lasting more than two hours, planned fasting over 12 hours, or fever over 101°F) and when to seek emergency evaluation (urine ketones moderate or large, confusion, or inability to keep liquids down).

Monitoring Parameters

Blood Pressure

Patients new to Jardiance should measure supine and standing blood pressure weekly for the first month. Adding regular cannabis use to that period increases the orthostatic risk window. A standing systolic drop of 20 mmHg or more from supine, or symptoms of dizziness within three minutes of standing, warrants prescriber contact.

Ketone Monitoring

Home urine ketone strips cost under ten dollars per box and provide a reliable early warning for DKA. Any cannabis user on Jardiance who experiences prolonged nausea or vomiting should check ketones immediately. Urine ketones of 1+ or higher on a standard strip in a symptomatic patient should prompt same-day provider contact or emergency evaluation [7].

Renal Function and Electrolytes

SGLT2 inhibitors can raise serum creatinine transiently, particularly during volume depletion. Cannabis-related dehydration from vomiting or reduced fluid intake compounds this. Patients should have a basic metabolic panel within the first three months of starting empagliflozin and annually thereafter, or sooner if they develop significant intercurrent illness [4].

Special Populations

Older Adults

Adults over 65 are at highest risk for orthostatic hypotension from the empagliflozin-cannabis combination. The EMPA-REG OUTCOME trial enrolled patients with a mean age of 63.1 years, and post-hoc analyses showed higher rates of volume-depletion adverse events in participants over 75 [3]. Cannabis use in older adults has increased substantially: the CDC reported that past-year cannabis use among adults 65 and older rose from 2.4% in 2015 to 4.2% in 2018, and trend data suggest continued increases [15].

Patients with Chronic Kidney Disease

Empagliflozin is now approved for chronic kidney disease (CKD) based on the EMPA-KIDNEY trial (N=6,609), which showed a 28% reduction in kidney disease progression or cardiovascular death (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) [16]. Patients with CKD have reduced renal reserve and are more vulnerable to acute kidney injury during volume depletion. Cannabis-induced vomiting in a patient with CKD on empagliflozin represents a genuine acute kidney injury risk, not just a theoretical one.

Patients with Heart Failure

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the composite of cardiovascular death or hospitalized heart failure by 25% versus placebo in patients with HFrEF [17]. Heart failure patients are often on multiple diuretics and are precariously volume-balanced. THC-induced vasodilation in that population could precipitate symptomatic hypotension. Cannabis use in heart failure patients on empagliflozin should be discussed explicitly with a cardiologist.

Summary of Interaction Risks by Category

| Interaction Type | Mechanism | Severity | Evidence Level | |---|---|---|---| | Additive hypotension | CB1 vasodilation plus SGLT2 diuresis | Moderate | Mechanistic plus case reports | | Euglycemic DKA (CHS) | Vomiting reduces carbohydrate intake during ketogenic SGLT2 state | High | FDA safety signal plus mechanistic | | Glucose symptom masking | Cannabis impairs hypothalamic glucose sensing | Low-moderate (monotherapy) | Preclinical plus observational | | Pharmacokinetic (CBD-UGT1A9) | CBD inhibits UGT1A9 in vitro | Unknown | In vitro only | | Appetite and glycemic variability | THC increases caloric intake | Low | Observational |